Analyst firms · Morgan Stanley · JNJ

Morgan Stanley JNJ price target and rating history

Johnson & Johnson (JNJ) · Health Care

Morgan Stanley rates Johnson & Johnson (JNJ) Overweight with a $262 price target, as of its latest action on Jan 28, 2026. It has published 4 rating actions on JNJ since September 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a JNJ price target in the last 12 months, the median target is $263.50. Morgan Stanley's $262 is 1% below that.

Current rating
Overweight
Price target
$262
Median target, all firms
$263.50
Actions on JNJ
4

Morgan Stanley price target on JNJ

$262$218$17320222023202420252026
Morgan Stanley price target on JNJ, each point a stated target, September 2021 to January 2026.

Every Morgan Stanley rating on JNJ

How other firms rate JNJ

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Erste GroupHoldOct 21, 2026
UBSBuy$320Sep 2, 2026
Leerink PartnersOutperform$265May 13, 2026
TD CowenBuy$250Apr 8, 2026
Morgan StanleyOverweight$262Jan 28, 2026

Questions about Morgan Stanley and JNJ

What is Morgan Stanley's price target for JNJ?
Morgan Stanley's latest stated price target for Johnson & Johnson (JNJ) is $262, from its action on Jan 28, 2026.
What is Morgan Stanley's rating on JNJ?
Morgan Stanley rates JNJ Overweight, a bullish rating, as of Jan 28, 2026.
When did Morgan Stanley last change its view on JNJ?
On Jan 28, 2026, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $262.
How does Morgan Stanley's JNJ target compare with other analysts?
Across 4 firms with a JNJ price target in the last 12 months, the median target is $263.50. Morgan Stanley's $262 is 1% below that.

More JNJ rating histories

All Morgan Stanley ratingsJNJ news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.